Search Within

Katherine Jessica Whitaker

Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
  3. Research Letter (1)
Groups
  1. Adult Leukemia (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Hematologic Malignancies, Division of (5)
  5. Lymphoma (3)
  6. Clinical Pharmacy Specialists (1)

More Groups

People
  1. Anthony Mato (5)
  2. Lindsey Roeker (5)
  3. Andrew Zelenetz (3)
  4. Colleen Dorsey (3)
  5. Amber King (2)
  6. Julie Goodfriend (2)

More People

Years
  1. 2021 (1)
  2. 2020 (1)
  3. 2019 (3)
Publications
  1. Blood (3)
  2. Clinical Cancer Research (1)
  3. Haematologica (1)
Publishers
  1. American Society of Hematology (3)
  2. American Association for Cancer Research (1)
  3. Ferrata Storti Foundation (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
    Research Letter

    Eyre, T. A.; Lamanna, N.; Roeker, L. E.; Ujjani, C. S.; Hill, B. T.; Barr, P. M.; Lansigan, E.; Cheson, B. D.; Yazdy, M.; Allan, J. N.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy
    Journal Article

    Mato, A. R.; Roeker, L. E.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D.; Shadman, M.; Ujjani, C. S.; Yazdy, M. S.; Perini, G. F.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: A retrospective analysis of real world patients
    Meeting Abstract

    Yazdy, M. S.; Mato, A. R.; Roeker, L. E.; Jarral, U.; Ujjani, C. S.; Shadman, M.; Skarbnik, A.; Whitaker, K. J.; Deonarine, I.; Kabel, C. C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Veneto-STOP study: Sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients
    Meeting Abstract

    Ujjani, C. S.; Roeker, L. E.; Shadman, M.; Whitaker, K. J.; Jacob, A. P.; Geyer, M. B.; Dorsey, C.; Zelenetz, A. D.; Mato, A. R.
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
    Blood (2019)

    Fulltext@MSK | Save